V114 Medium Dose + V114 High Dose + V114 Medium Dose with Alternative Carrier Protein + V114 High Dose with Alternative Carrier Protein + Prevnar 13™
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pneumococcal Infections
Conditions
Pneumococcal Infections
Trial Timeline
Sep 15, 2015 → Apr 14, 2017
NCT ID
NCT02531373About V114 Medium Dose + V114 High Dose + V114 Medium Dose with Alternative Carrier Protein + V114 High Dose with Alternative Carrier Protein + Prevnar 13™
V114 Medium Dose + V114 High Dose + V114 Medium Dose with Alternative Carrier Protein + V114 High Dose with Alternative Carrier Protein + Prevnar 13™ is a phase 1/2 stage product being developed by Merck for Pneumococcal Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT02531373. Target conditions include Pneumococcal Infections.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02531373 | Phase 1/2 | Completed |
Competing Products
20 competing products in Pneumococcal Infections